These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32508358)

  • 1. Impact of Clinical, Unit-Specific Guidelines on Dornase Alfa Use in Critically Ill Pediatric Patients Without Cystic Fibrosis.
    Tester C; Raiff D; Heath T
    Hosp Pharm; 2020 Jun; 55(3):199-203. PubMed ID: 32508358
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey.
    den Hollander B; Linssen RSN; Cortjens B; van Etten-Jamaludin FS; van Woensel JBM; Bem RA;
    Eur J Hosp Pharm; 2022 May; 29(3):123-128. PubMed ID: 33122405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Inhaled Dornase Alfa Administration in Non-Cystic Fibrosis Patients at a Tertiary Academic Medical Center.
    Torbic H; Hacobian G
    J Pharm Pract; 2016 Oct; 29(5):480-3. PubMed ID: 25667210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dornase alfa in pediatric patients without cystic fibrosis.
    Daiya KC; Sierra CM
    Hosp Pract (1995); 2023 Apr; 51(2):89-94. PubMed ID: 36723457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dornase alfa for cystic fibrosis.
    Yang C; Chilvers M; Montgomery M; Nolan SJ
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dornase alfa for cystic fibrosis.
    Jones AP; Wallis C
    Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series.
    Weber AG; Chau AS; Egeblad M; Barnes BJ; Janowitz T
    medRxiv; 2020 May; ():. PubMed ID: 32511514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.
    Riethmueller J; Borth-Bruhns T; Kumpf M; Vonthein R; Wiskirchen J; Stern M; Hofbeck M; Baden W
    Pediatr Pulmonol; 2006 Jan; 41(1):61-6. PubMed ID: 16265663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pharmacy services on cystic fibrosis medication adherence.
    Zobell JT; Schwab E; Collingridge DS; Ball C; Nohavec R; Asfour F
    Pediatr Pulmonol; 2017 Aug; 52(8):1006-1012. PubMed ID: 28608652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quality Improvement Approach to Influence Value-based Mucolytic Use in the PICU.
    Gillis HC; Dolan K; Sargel CL; Thompson RZ; Lutmer JE
    Pediatr Qual Saf; 2021; 6(4):e438. PubMed ID: 34345751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007923. PubMed ID: 23737088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2011 May; (5):CD007923. PubMed ID: 21563162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007923. PubMed ID: 27457496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis.
    Thornby KA; Johnson A; Axtell S
    Ann Pharmacother; 2014 Aug; 48(8):1040-1049. PubMed ID: 24811400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.